4.3 Article

Treatable cardiac disease in hospitalised COPD exacerbations

Journal

ERJ OPEN RESEARCH
Volume 7, Issue 1, Pages -

Publisher

EUROPEAN RESPIRATORY SOC JOURNALS LTD
DOI: 10.1183/23120541.00756-2020

Keywords

-

Funding

  1. Australian National Health and Medical Research Council Postgraduate Scholarship
  2. Royal Australasian College of Physicians Dixon Award
  3. Monash Lung and Sleep Institute

Ask authors/readers for more resources

Dynamic CT can detect clinically silent CAD and HFrEF during hospitalised AECOPD, offering opportunities to improve outcomes through established cardiac treatments. The prevalence of severe CAD was 35%, left ventricular systolic dysfunction was found in 8% of cases, and right ventricular systolic dysfunction was present in 12% of cases among patients with hospitalised AECOPD.
Introduction: Acute exacerbations of COPD (AECOPD) are accompanied by escalations in cardiac risk superimposed upon elevated baseline risk. Appropriate treatment for coronary artery disease (CAD) and heart failure with reduced ejection fraction (HFrEF) could improve outcomes. However, securing these diagnoses during AECOPD is difficult, so their true prevalence remains unknown, as does the magnitude of this treatment opportunity. We aimed to determine the prevalence of severe CAD and severe HFrEF during hospitalised AECOPD using dynamic computed tomography (CT). Methods: A cross-sectional study of 148 patients with hospitalised AECOPD was conducted. Dynamic CT was used to identify severe CAD (Agatston score >= 400) and HFrEF (left ventricular ejection fraction <= 40% and/or right ventricular ejection fraction <= 35%). Results: Severe CAD was detected in 51 of 148 patients (35%), left ventricular systolic dysfunction was identified in 12 cases (8%) and right ventricular systolic dysfunction was present in 18 (12%). Clinical history and examination did not identify severe CAD in approximately one-third of cases and missed HFrEF in two-thirds of cases. Elevated troponin and brain natriuretic peptide did not differentiate subjects with severe CAD from nonsevere CAD, nor distinguish HFrEF from normal ejection fraction. Undertreatment was common. Of those with severe CAD, only 39% were prescribed an antiplatelet agent, and 53% received a statin. Of individuals with HFrEF, 50% or less received angiotensin blockers, beta blockers or antimineralocorticoids. Conclusion: Dynamic CT detects clinically covert CAD and HFrEF during AECOPD, identifying opportunities to improve outcomes via well-established cardiac treatments.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available